01 August 2013 10:22 [Source: ICIS news]
LONDON (ICIS)--Sanofi’s second-quarter business net income fell by 23% year on year on a reported basis to €1.48bn ($1.97bn) on the back of the expiry of certain key patents, the France-based pharmaceutical firm said on Thursday.
Net sales for the quarter fell by 9.8% to €8.0bn from the same period in 2012, principally impacted by sales lost due to generic competition, while earnings per share decreased by 24% to €1.11.
Sanofi CEO Christopher Viehbacher said: “The second quarter was a difficult quarter. As expected, this was the last quarter with a tough comparison to the prior year due to the residual impact of the patent cliff.
“Sales were also affected by our business in Brazil and commercial underperformance in certain business areas.”
Viehbacher said the company continues to expect to return to growth in the second half of 2013.
($1 = €0.75)
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections